Form 4: Aquestive Therapeutics Director Receives Stock Options

Director Julie Krop was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a standard equity compensation plan.

Summary

• Director Julie Krop received a grant of 50,500 stock options on June 10, 2026.
• The options have an exercise price of $3.99 per share.
• The options are scheduled to vest in full on June 10, 2027, contingent upon continued service.
• The expiration date for these options is June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.
• Standard vesting schedule encourages retention of key leadership.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• Market price volatility could impact the future value of the granted options.
• Vesting is subject to the director's continuous service with the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation of a director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure alignment between board members and shareholders.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is consistent with standard practices for mid-cap pharmaceutical and biotech companies.
• The one-year cliff vesting period is a common retention mechanism used by peers in the industry.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 10, 2027.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Director Compensation, Stock Options, SEC Form 4, Insider Transaction